Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
TaskUs Q1 2026 Earnings Call - AI Services Surge Offsets Largest Client Automation Headwinds
TaskUs delivered a resilient Q1 2026, beating top-end revenue guidance by $8.3 million and generating $58.6 million in adjusted EBITDA. The standout story is AI Services, which grew 36% year-over-year...
- Q1 revenue of $306.3 million beat the top end of guidance by approximately 3%, with year-over-year growth of 10.3%.
- AI Services is the primary growth engine, surging 36% year-over-year to $61.9 million, with over 40% of Q1 signings attributed to this segment.
- Growth excluding the largest client was robust at 13.5% year-over-year, with clients 2 through 20 growing well north of 20%.
- +7 more takeaways
Stem, Inc. Q1 2026 Earnings Call - First Ever Positive Q1 Adjusted EBITDA Driven by Software Margin Expansion and Utility Scale Momentum
Stem delivered its first positive adjusted EBITDA in a first quarter, marking the fourth consecutive quarter of profitability as the company's 2025 transformation takes hold. Core software and service...
- Stem reported its first-ever positive adjusted EBITDA in a first quarter, generating $2 million and marking the fourth consecutive quarter of profitability.
- Non-GAAP gross margins expanded to a record 52% in Q1, driven by a revenue mix shift toward higher-margin software, services, and edge hardware, with no battery hardware resales this quarter.
- PowerTrack software revenue grew 16% year-over-year, while core revenue (software, services, edge hardware) rose 4% year-over-year, offsetting an 11% decline in total revenue caused by the absence of battery hardware resales.
- +7 more takeaways
Compass Diversified Holdings (CODI) Q1 2026 Earnings Call - Double-Digit Consumer Growth Offsets Industrial Headwinds
Compass Diversified Holdings (CODI) delivered a quarter of disciplined execution, highlighted by the successful sale of Sterno’s food service business and double-digit EBITDA growth in its consumer po...
- CODI sold Sterno’s food service business at an attractive valuation, reducing total leverage to ~5.0x and senior secured net leverage to below 1.0x.
- Consumer businesses drove double-digit subsidiary-adjusted EBITDA growth, led by The Honey Pot (nearly 25% revenue growth) and BOA (11% EBITDA growth).
- Industrial businesses faced mixed results: Arnold nearly doubled EBITDA due to geopolitical tailwinds, while Altor faced cold chain and consumer headwinds.
- +7 more takeaways
Agilon Health Q1 2026 Earnings Call - Raised Full-Year Outlook on Stronger Risk Scores and Payer Contracts
Agilon Health delivered a first quarter that exceeded expectations, driven by better-than-anticipated risk adjustment revenue and disciplined execution across its value-based care model. The company r...
- Agilon Health raised its full-year 2026 revenue guidance to approximately $5.7 billion, medical margin to $375 million, and Adjusted EBITDA to $25 million, citing stronger-than-expected first-quarter performance.
- First-quarter revenue was $1.42 billion, exceeding the top end of guidance, driven by higher estimated risk scores and a new full-risk contract with a new payer in an existing market.
- Medicare Advantage membership declined to 426,000 from 491,000 year-over-year, reflecting strategic market exits and a disciplined, profitability-focused approach to growth.
- +7 more takeaways
Tutor Perini Q1 2026 Earnings Call - Record Cash Flow and Backlog Fuel 2026 Confidence
Tutor Perini kicked off 2026 with its strongest first quarter since 2009, posting record operating cash flow of $147 million and $1.4 billion in revenue, up 11% year-over-year. The company’s backlog r...
- Record operating cash flow of $147 million, up 542% year-over-year, driven by improved collections and working capital management.
- Revenue grew 11% to $1.4 billion, marking the highest first-quarter revenue since 2009, fueled by larger, higher-margin projects in the civil and building segments.
- Backlog remains strong at $19.8 billion, with nearly $700 million in new awards booked in Q1, primarily in California.
- +7 more takeaways
Arm FY2026 Q4 Earnings Call - Record Revenue and Agentic AI CPU Demand Surge
Arm reported a record $1.49 billion in fourth-quarter revenue, up 20% year-over-year, and a full-year total of $4.92 billion, up 23%. The results were driven by surging demand for its Neoverse IP and ...
- Arm delivered record Q4 FY2026 revenue of $1.49 billion, up 20% year-over-year, and a full-year total of $4.92 billion, up 23%.
- Non-GAAP EPS hit a record $0.60 in Q4, driven by strong royalty and licensing growth despite continued R&D investment.
- Royalty revenue grew 11% to $671 million, with data center royalties more than doubling year-over-year due to hyperscaler adoption.
- +7 more takeaways
Root, Inc. Q1 2026 Earnings Call - Record Profitability Driven by AI Underwriting and Disciplined Capital Allocation
Root, Inc. delivered its most profitable quarter in company history during Q1 2026, with record net income of $36 million and an annualized return on equity of 47%. The results were driven by structur...
- Record Q1 2026 profitability with net income of $36 million and an annualized ROE of 47%, marking the highest quarterly profit in company history.
- Policies in force grew 9% year-over-year, while gross premiums written reached $389 million, though premium growth moderated due to prior-year tariff-related demand.
- Partnership and independent agent channels surged 30% year-over-year, with over 15,000 agents now partnered and a new distribution agreement with Freeway Insurance.
- +7 more takeaways
Sarepta Therapeutics Q1 2026 Earnings Call - ELEVIDYS Stabilization and siRNA Pipeline Acceleration
Sarepta Therapeutics reported Q1 2026 results that underscore a business stabilizing after the turbulence of 2025. Total revenue came in at $731 million, driven by $331 million in net product sales sp...
- Total revenue of $731 million in Q1 2026, a 2% year-over-year decrease, driven by lower ELEVIDYS sales partially offset by collaboration revenue.
- Net product revenue was $331 million, comprising $229 million from the PMO franchise and $102 million from ELEVIDYS.
- The company reported a GAAP operating profit of $358 million, supported by $400 million in collaboration and milestone revenue, including a $325 million non-cash item from Roche.
- +7 more takeaways
Encore Capital Group Q1 2026 Earnings Call - Record Collections and Raised Guidance Signal a Strong Credit Cycle
Encore Capital Group delivered a standout first quarter in 2026, driven by record global collections of $718 million and aggressive portfolio purchasing of $363 million. The company's U.S. debt buying...
- Record global collections surged 19% year-over-year to $718 million, driven by strong execution and operational innovation in the U.S. market.
- Global portfolio purchases reached $363 million, with 87% of capital deployed in the U.S. to capitalize on abundant supply and attractive returns.
- U.S. charge-off rates remain at their highest level in over a decade, creating a robust and stable supply environment for debt buyers.
- +7 more takeaways
Clover Health Q1 2026 Earnings Call - GAAP Profitability Hits $27M as Membership Surges 51%
Clover Health reported a decisive shift in its Medicare Advantage strategy during Q1 2026, achieving GAAP net income of $27 million while expanding membership by 51% year-over-year to 156,000 lives. T...
- GAAP net income reached $27 million, a $29 million year-over-year improvement, proving the model can scale profitability alongside rapid growth.
- Medicare Advantage membership surged 51% year-over-year, adding over 52,000 lives to reach approximately 156,000 members.
- Total revenue jumped 62% year-over-year to $749 million, reflecting both enrollment gains and favorable medical cost performance.
- +12 more takeaways